Introduction
Human herpesvirus (HHV)-6 is a member of the Roseolovirus genus in the Betaherpesvirinae subfamily of human herpesviruses. Two variants of HHV-6 (A and B) have been identified. 1 The clinical significance of HHV-6A remains unclear. HHV-6B is the causative agent of exanthema subitum. HHV-6 is transmitted through saliva 2 and infects virtually all children within the first few years of life. 3, 4 Like the other herpesviruses, HHV-6 is capable of persisting in the host after primary infection, and can reactivate from latency under conditions of immunosuppression. Most HHV-6 infections in immunosuppressed patients are due to reactivation of HHV-6B. 5 8 The accumulated data indicate that HHV-6 represents an emerging and potentially life-threatening pathogen for recipients of allogeneic hematopoietic cell transplantation 
Diagnosis of HHV-6 reactivation
Serological determination of either immunoglobulin (Ig)
G or IgM has no significance for the diagnosis of active HHV-6 infection or disease in HCT recipients. Several methods have been used to diagnosis HHV-6 reactivation, including: virus isolation; 9 PCR assay; 7, 10 18 and antigenemia assay. 19 Currently, direct detection of HHV-6 DNA using PCR
The persistence of positive result in whole blood may reflect latent infection in leukocytes. Although approaches using whole blood may still offer some advantages, 22, 23 detection of HHV-6 DNA in plasma or serum correlates well with active replication and may be more directly interpretable. 24 26 Careful interpretation is needed for results of HHV-6 DNA in peripheral blood. First, the unique phenomenon of HHV-6 chromosomal integration may account for abnormally high levels of HHV-6 DNA. This condition has been termed chromosomally integrated HHV-6 (ciHHV-6) or inherited HHV-6 . The complete HHV-6 genome becomes integrated into the host germ in an individual with ciHHV-6 and is vertically transmitted in a Mendelian manner. 27 The condition is found in less than 1% of controls in the United States and United Kingdom. 27 Although there are suggestions that ciHHV-6 can be induced to a state of lytic viral replication in vitro, 27 little is known about the pathogenic role of ciHHV-6 in allo-HCT recipients. The possibility of ciHHV-6 should be considered when high viral DNA loads in peripheral blood persist despite an absence of clinical symptoms of HHV-6-associated disease. In situations where a donor has ciHHV-6, HHV-6 DNA load in the recipient will increase with engraftment. 28 The most practical method to confirm ciHHV-6 status is quantitative PCR using whole blood. 27 If a donor has ciHHV-6, the recipient will show one or more copies per white blood cell after engraftment, corresponding to 5>.5 log 10 copies/ml of whole blood. 27 Second, as shown later, HHV-6 reactivation is common after allo-HCT, and most reactivations are asymptomatic. It is important to consider multiple potential causes, because the presence of HHV-6 DNA in peripheral blood does not necessarily prove causality.
Third, the duration of positive HHV-6 DNA in plasma is short after allo-HCT. If sampling time is delayed for several days after the onset of HHV-6-associated complications, the HHV-6 DNA load may already be in decline. Fourth, methods of real-time PCR to quantify HHV-6 DNA loads have not been standardized. Results for HHV-6 viral loads in the same specimen thus now differ considerably among several laboratories.
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HHV-6 reactivation after allo-HCT
Overall, HHV-6 has been shown to reactivate in 30 50%
of patients undergoing allo-HCT. 7, 9, 12, 15 18 HHV-6 appears most frequently around 2 4 weeks after allo-HCT, 7, 9, 13, 17, 18 and 0 9 days after neutrophil engraftment. 17 HHV-6 can reactivate to high levels within a week, 17 but the duration of HHV-6 reactivation is usually short. 17 Most HHV-6 infections are due to reactivation of HHV-6B, 7, 8 with type A isolated in 2 3% by HHV-6 subtyping. Figure 1 shows the incidence of positive plasma HHV-6 DNA and the associated kinetics in 178 patients who underwent allo-HCT in the Oita Group (Oita University Hospital and Oita Prefectural Hospital). 30 As previously reported, HHV-6 reactivation was typically detected 2 4 weeks after transplantation. u n r e l a t e d t r a n s p l a n t s ; 16, 17 14, 18 and low anti-HHV-6 IgG titer before transplantation. 18 Among these, steroid administration 17 and UCBT 14 are also associated with higher-level HHV-6 reactivation.
Pathogenicity of HHV-6
The host tissue range of HHV-6 in vivo includes peripheral blood mononuclear cells, 31 42 HHV-6 infection is associated with selective suppression of interleukin 12 production, an important cytokine for antiviral immune response. 43 As a result, this suppression drives the immune balance toward a Th2 response. HHV-6 impairs intracellular signaling through Toll-like receptor. 44 Disruption of antiviral immune response may represent a strategy by which viruses can evade the immune surveillance system, and this mechanism may facilitate immunosuppression in allo-HCT recipients.
Unsurprisingly, then, HHV-6 reactivation is also associated with subsequent cytomegalovirus (CMV) reactivation. 45 In contrast to the in vitro evidence of HHV-6-induced immunosuppressive effects, HHV-6 reactivation in allo-HCT may induce pro-inflammatory response. Recent large-scale studies have demonstrated associations between HHV-6 reactivation and subsequent graft-versus-host disease (GVHD). 45, 46 In those studies, the authors speculated that immune-mediated responses such as activation of alloreactive T cell 46 or the pro-inflammatory or type I immune responses induced by HHV-6 reactivation 45 play a role in the development of GVHD. Another report showed an association between HHV-6 reactivation and elevated serum cytokine levels. 47 Immune-mediated responses to HHV-6 may promote the development of subsequent immunological complications.
HHV-6 is recognized as an important pathogen affecting the nervous system. 48 The possible pathogenicity of HHV-6 in the development of encephalitis following allo-HCT is discussed in the HHV-6 encephalitis section. Hospital. Taken from [30] .
HHV-6-associated complications
undermined and careful interpretation of disease associations is still required.
HHV-6 encephalitis
Currently, both terms HHV-6 encephalitis and HHV-6 encephalopathy are widely used. This may be because the pathogenicity of HHV-6 for CNS disease has not been elucidated in sufficient detail; some investigators may feel that using encephalitis requires evidence of tissue inflammation by HHV-6. In this article, HHV-6 encephalitis is used, because this term seems to be more commonly used. Characteristics of HHV-6 encephalitis following allo-HCT are summarized in Table 1 .
Clinical presentation: Zerr performed a review of 48 allo-HCT recipients with HHV-6-associated encephalitis previously described in the literature. 25 Onset of encephalitis began on a median of day 24. Symptoms were characterized by short-term memory loss, depressed consciousness, confusion, disorientation and clinical seizure. Magnetic 
Secondary complications
Syndrome of inappropriate secretion of ADH
Diagnosis
Presence of neurological symptoms, positive HHV-6 DNA in the CSF, and the absence of other identified etiologies of CNS dysfunction
Differential diagnosis includes encephalitis due to other pathogens, PRES, TMA, and adverse drug effects Results shown in both analyses were similar and therefore indicate characteristics of HHV-6 encephalitis. In summary, HHV-6 encephalitis typically develops around 3 weeks (2 6 weeks) after allo-HCT, the typical initial symptom is shortterm memory loss with subsequent progression to loss of consciousness, confusion, and seizure. MRI typically showed bilateral signal abnormalities in the limbic system. Figure 2 shows MRI findings of the brain in a patient who developed HHV-6 encephalitis in our institute. Focal abnormalities in limbic system have been identified.
HHV-6 encephalitis typically develops several days after bone marrow engraftment. 17, 50, 51 In UCBT recipients, however, HHV-6 encephalitis may tend to develop before engraftment. A single center study analyzing 1344 allo-HCT recipients (19 of whom developed HHV-6 encephalitis) 52 showed onset of HHV-6 encephalitis symptoms before engraftment in 7 of 10 patients who underwent UCBT, compared to only 1 of 9 adult donor recipients.
Incidence and risk factors:
Several studies that performed monitoring of HHV-6 viral load have demonstrated associations between systemic HHV-6 reactivation and CNS dysfunction. 7, 13, 17, 18, 50, 53 Incidence ranged from 3.6% to 8%.
Retrospective observations conducted by several Japanese allo-HCT units 17, 53 58 have shown a high incidence of HHV-6-associated CNS dysfunction in each institute (4 11.4% of allo-HCT recipients).
The incidence of HHV-6 encephalitis is strongly dependent on the selection of stem cell source. A review of allo-HCT recipients with HHV-6 encephalitis 25 showed that approximately 85% of these cases developed in recipients of unrelated or HLA mismatched-related allo-HCT. In particular,
UCBT has been recognized as a strong risk factor for HHV-6 encephalitis. A single center retrospective study in Japan analyzing 228 allo-HCT recipients 55 showed a significant correlation between HHV-6 encephalitis/myelitis and UCBT (15.7% in UCBT; 2.8% in bone marrow or peripheral blood stem cells, P 0.005). In a single-center study analyzing 1344 patients undergoing allo-HCT, 52 the incidence of HHV-6 encephalitis was 9.9% after UCBT and 0.7% after adultdonor HCT (adjusted hazard ratio [aHR], 20.0; P 0.001).
Post-transplant immune reactions, such as pre-engraftment immune reaction (PIR), engraftment syndrome, and GVHD, in Case 1 was taken from [98] , and both images in Case 2 were taken from [51] .
These images show symmetrical hyperintensities in the limbic system (hippocampus and amygdala).
may be associated with the development of HHV-6 encephalitis. 52, 53, 55 Mori et al. reported that all of 13 patients with HHV-6 encephalitis/myelitis presented with PIR prior to the onset of encephalitis. 55 Another study reported among patients with high-level HHV-6 reactivation, GVHD or engraftment syndrome was a significant risk factor for subsequent development of HHV-6 encephalitis. 53 That study showed elevated serum interleukin-6 concentration preceding the development of HHV-6 encephalitis. 53 alemtuzumab. 59 The roles of these factors remain undetermined. 65 Not only high-level HHV-6 reactivation, but also a hypercytokinemic state preceding HHV-6 reactivation is associated with progression to HHV-6 encephalitis. 53 Furthermore, HHV-6-negative post-transplant acute limbic encephalitis has been reported. 63 Such findings suggest the existence of multiple pathogenic mechanisms, including immune attack, underlying the CNS manifestations of HHV-6 encephalitis. 51 Further exploration of the pathogenesis of HHV-6 encephalitis is needed. 67 70 In patients showing distinctive CNS symptoms, high levels of plasma HHV-6 DNA are suggestive of HHV-6 encephalitis, and may allow earlier initiation of treatment. 17, 18, 50, 53 A study of weekly monitoring for plasma HHV-6 DNA in 111 HSCT recipients 53 showed that incidences of HHV-6 encephalitis were 0%, 33.3%, and 66.7% in patients with peak HHV-6 DNA levels of 10 4 copies/ml, 10 4 -10 5 copies/ml, and ≥ 10 5 copies/ml offered 71% sensitivity and 94% specificity for a diagnosis of HHV-6 encephalitis. 52 These findings indicate the potential diagnostic performance of plasma HHV-6 DNA in identifying cases of HHV-6 encephalitis. However, careful interpretation is needed. The duration of positive HHV-6 DNA in plasma is short. 17, 50, 53 Without routine monitoring, the peak value of HHV-6 DNA may be missed. Less than half of patients with high-level plasma HHV-6 DNA (i.e., ≥ 10 4 copies/ml) develop HHV-6 encephalitis, and, conversely, patients have been reported to develop HHV-6 encephalitis despite displaying low level HHV-6 DNA in plasma. 51, 71 HHV-6 encephalitis is typically accompanied by an MRI signature of hyperintense lesions on T2-weighted, fluid attenuation inversion recovery, and diffusion-weighted imaging of bilateral medial temporal lobes, primarily affecting the hippocampus and amygdala (Fig. 2) . Prevention: ECIL does not recommend antiviral prophylaxis against HHV-6, due to the low risk of HHV-6 disease and the toxicity associated with available antiviral drugs. 20 Actually, no available data have demonstrated any significant efficacy of prophylactic antiviral therapy to prevent HHV-6 encephalitis in allo-HCT recipients. However, HHV-6 encephalitis is not rare, particularly among UCBT recipients. 52, 55 The efficacy of antiviral treatment appears insufficient if HHV-6 encephalitis has developed. Many investigators assert that efforts should be made to establish methods to prevent HHV-6 encephalitis at high risk of this complication. 50, 55, 57, 81, 82 Preemptive approaches against asymptomatic CMV reactivation can successfully prevent the development of CMV pneumonia. 83, 84 Two small trials have provided data on the efficacy of plasma HHV-6 DNA-guided preemptive therapy to prevent HHV-6 encephalitis. 50, 85 However, these preemptive approaches cannot prevent the development of HHV-6 encephalitis due to the dynamic kinetics of plasma HHV-6 DNA.
Pathogenesis
Diagnosis
A study of allo-HCT recipients with unrelated bone marrow or UCBT comparing consecutive cohorts of patients not receiving prophylaxis (cohort 1, n 51) with those receiving PFA prophylaxis (cohort 2, n 67) has recently been reported. 51 The prophylactic regimen was 50 mg/kg/day of PFA for 10 days after engraftment. No significant reduction in high-level reactivation (HHV-6 DNA ≥ 10 4 copies/ml) by day 70 was seen in Cohort 2 (19.4%) compared with Cohort 1 (33.8%, P 0.095). Breakthrough HHV-6 encephalitis occurred following PFA prophylaxis in 3 patients (Figure 3) , and the incidence of HHV-6 encephalitis did not differ between Cohort 1 (9.9%) and Cohort 2 (4.5%, P 0.24). The results of that study showed that 50 mg/kg/day of PFA for 10 days after engraftment did not effectively suppress HHV-6 reactivation and did not prevent all cases of HHV-6 encephalitis.
Clinical trials using an increased dose of prophylactic PFA, or using other compounds such as lipid esters of CDV, 82, 86 for a longer period in high-risk patients may be warranted. Alternative approaches based on the pathogenesis of HHV-6 encephalitis will be required in the next step.
CNS dysfunction other than encephalitis due to HHV-6 infection
A well-designed, prospective study of 315 allo-HCT recipients 81 demonstrated an independent association between HHV-6 reactivation and subsequent delirium, as indicated by neuropsychiatric screening. HHV-6 reactivation was also independently associated with subsequent neurocognitive decline at approximately 3 months after allo-HCT, as measured by baseline and follow-up neurocognitive testing.
In that study, no typical imaging abnormalities associated with HHV-6 encephalitis were confirmed in any of the 9 patients who underwent brain MRI. Those findings suggest that HHV-6 may lead to CNS dysfunction in the absence of encephalitis.
Myelitis may occur due to HHV-6 reactivation. Mori et al.
reported two patients who developed HHV-6-associated myelitis after UCBT. 87 A single-center study analyzing 228 allo-HCT recipients 55 identified a total of 11 patients with HHV-6 myelitis; 4 patients presented only with dysesthesia and pruritus, and 7 patients showed both symptoms of encephalitis and myelitis. All 4 patients presenting only with myelitis symptoms were UCBT recipients. HHV-6 myelitis may be associated with UCBT.
Bone marrow suppression/graft failure
Many studies have shown that HHV-6 reactivation is associated with bone marrow suppression 7, 12, 16, 88 or delayed p l a t e l e t e n g r a f t m e n t . 7, 10, 12, 13, 17, 46 L j u n g m a n e t a l . encephalitis, four never achieved engraftment. 52 HHV-6 may be considered as a differential diagnosis for secondary graft failure after allo-HCT.
Lung disease
HHV-6 may be a potential cause of unexplained interstitial pneumonia after allo-HCT. 14, 96 99 In patients who developed interstitial pneumonia after allo-HCT, HHV-6 infection of the lung was demonstrated by immunohistochemical staining on lung tissue, 96 PCR study of lung biopsy specimens 97 or PCR study of bronchoalveolar lavage samples. 99 Sauter et al. 100 reported the computed tomography (CT) findings of HHV-6 pneumonitis: beginning as perihilar and bilateral septal thickening, reticulation, and ground-glass opacity and extending from both central areas, turning into a crazy-paving pattern of infiltration followed by lung parenchymal consolidation. Figure 4 shows lung CT from a patient who developed HHV-6 pneumonitis in our institute. 99 HHV-6
DNA load in bronchoalveolar lavage fluid was 6.8 10 6 copies/ ml, and no other pathogens were identified. Differentiation between HHV-6 pneumonitis and idiopathic pneumonia syndrome may be important, because specific antiviral therapies may influence the course of HHV-6 pneumonitis.
To date, only a small number of definitive HHV-6-associated cases have been reported. Further investigation is needed to clarify the incidence and significance of HHV-6 pneumonitis after allo-HCT.
Gastrointestinal disease
Hentrich et al. have reported that HHV-6 was detected in gastric (n 14) and duodenal (n 11) biopsies in 23 patients complaining of gastrointestinal symptoms. 16 Amo et al.
reported that HHV-6B DNA was demonstrated in the nuclei of goblet cells by in situ hybridization in patients with severe diarrhea. 101 A recent retrospective single-center analysis including 50 patients with severe vomiting and diarrhea after allo-HCT showed that HHV-6 DNA was detected in 51% of initial biopsy specimens of gastrointestinal tract. 102 That study showed detection of HHV-6 DNA in biopsy specimens was not associated with overall survival and antiviral therapy against HHV-6 provided no beneficial effects. 102 PCR for HHV-6 DNA in biopsy specimens may be too sensitive to diagnose clinically relevant HHV-6 infection. Further studies investigating HHV-6 antigen expression on pathological mucosa are needed to elucidate whether HHV-6 causes gastrointestinal disease in HSCT recipients, as seen in CMV infection.
Liver disease
A few allo-HCT recipients with HHV-6-associated liver disease have been reported. 13, 103 In one patient, HHV-6 was detected in a liver biopsy along with histopathological changes suggestive of viral hepatitis, high levels of HHV-6
and no other explanations for the hepatitis. 13 However, demonstrating HHV-6 as a causative pathogen for liver dysfunction in allo-HCT recipients is difficult, given the many potential causes of liver dysfunction, including GVHD, drug, and infectious agents. Carefully designed studies are needed to determine the roles of HHV-6 in liver disease after allo-HCT.
GVHD
Many previous studies have reached conflicting conclusions regarding the role of HHV-6 in acute GVHD. 7, 12, 16, 104 107 Recent epidemiological studies analyzing 235 consecutive patients revealed a significant association between acute GVHD and HHV-6 reactivation. 46 This association was stronger for high-grade acute GVHD, and remained significant in patients who experienced HHV-6 reactivation before initiation of salvage immunosuppression for acute GVHD. 46 In that study, the authors suggested inflammatory responses to HHV-6 reactivation, effects of HHV-6 against the host immune system through various mechanisms, and activation of alloreactive T cells may have triggered acute GVHD. More recently, Zerr et al. 45 performed a large prospective study (n 315) to define HHV-6-associated sequelae after allo-HCT. That study revealed highlevel HHV-6 was associated with subsequent grade II-IV GVHD (HR, 2.7; P 0.02). The authors speculated that HHV-6 reactivation causes a pro-inflammatory or type I immune response, which would play a role in the development of acute GVHD. 45 
Rash
Early studies have shown associations between HHV-6 reactivation and rash. 9, 11, 19, 108, 109 Immunohistological examinations against of skin specimens from patients displaying rash concomitant with positive HHV-6 DNA in plasma 17 or skin 109 did not demonstrate expression of HHV-6
antigen. Distinguishing HHV-6-associated skin rash from rash due to acute GVHD may be difficult.
CMV infection
Several reports have shown associations between HHV-6 reactivation and CMV reactivation. 45, 110, 111 A recent prospective study 45 analyzing 315 allo-HCT recipients demonstrated that HHV-6 reactivation was independently associated with subsequent CMV reactivation (aHR, 1.9; P 0.002). The same study also demonstrated that high-level HHV-6 reactivation was strongly associated with increased risk of subsequent high-level CMV reactivation (aHR, 3.11; P 0.002). Whether HHV-6 induces CMV reactivation though its immunomodulatory effects, or whether more severe immunosuppression after allo-HCT accounts for the reactivation of both HHV-6 and CMV remains uncertain.
Future need
Over the past decade, HHV-6 encephalitis has become well known as a complication accompanying allo-HCT.
Currently, HHV-6 encephalitis may be recognized as the most feared CNS complication in UCBT recipients. Despite appropriate diagnosis and early initiation of treatment, the attributable mortality rate continues to be high (Table 2) .
Even in survivors, many patients are left with neurological compromise, making it difficult to return to society. 57 We should recognize that currently available treatments are recently demonstrated in a large-scale prospective study. 45 However, whether those associations are causal remains undetermined. Determination of the spectrum of HHV-6-associated diseases in allo-HCT recipients will be important, because antiviral agents can manage HHV-6 reactivation. If HHV-6 reactivation plays a causative role in the development of acute GVHD or CMV infection, reducing HHV-6 reactivation using antiviral agents for HHV-6 might lower the incidence of these complications.
Executive summary
Methods for diagnosing HHV-6 reactivation
